Salix Coronary Plaque vs EchoGo® Heart Failure
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A specializes in the assessment of coronary artery plaque and stenosis from CCTA scans for diagnosing coronary artery disease. In contrast, Tool B analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF). While both are FDA-cleared AI platforms in cardiology, they address distinct cardiac conditions using different imaging modalities, making them complementary rather than directly competitive.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Artrya Salix Coronary Plaque is designed to aid in the rapid and accurate diagnosis of coronary artery disease by assessing coronary artery plaque and stenosis from CCTA scans. Ultromics EchoGou00ae Heart Failure analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF).
Salix Coronary Plaque requires Coronary CT Angiography (CCTA) scans for its AI-enabled analysis. EchoGou00ae Heart Failure analyzes routine echocardiogram video clips to provide its insights.
Salix Coronary Plaque operates on a per-scan assessment model, with a US CPT reimbursement rate of US$950 per assessment, effective January 1, 2026. EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers.
Artrya Salix Coronary Plaque provides near real-time, point-of-care assessment, with results available in less than 10 minutes. Ultromics EchoGou00ae Heart Failure delivers its insights within 20 minutes of analyzing routine echo video clips.
Salix Coronary Plaque offers detection and quantification of coronary plaque, identification of high-risk plaque features, stenosis assessment, and quantification of calcifications. EchoGou00ae Heart Failure provides AI-powered HFpEF detection and automated structured reports based on echocardiogram analysis.
Salix Coronary Plaque is FDA-cleared, but specific clinical validation metrics like sensitivity or specificity are not explicitly detailed in the provided information. EchoGou00ae Heart Failure is clinically validated, demonstrating 90% sensitivity and 86% specificity for HFpEF detection, and was trained on over 10 years of outcome data.
Salix Coronary Plaque features integrated workflow management and automated report generation. EchoGou00ae Heart Failure offers seamless integration with existing workflows and IT stacks, including a DICOM workflow for report delivery to PACS.